imipramine has been researched along with darifenacin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bartuschat, A; Fischer, O; Fromm, MF; Gmeiner, P; Heinrich, MR; Hofmann, J; Hübner, H; Kaindl, J; Pratsch, G; Rampp, H; Taudte, RV | 1 |
1 review(s) available for imipramine and darifenacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for imipramine and darifenacin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists.
Topics: Aminobiphenyl Compounds; Animals; Caco-2 Cells; Drug Inverse Agonism; Halogens; HEK293 Cells; Humans; Male; Molecular Docking Simulation; Muscarinic Agonists; Muscarinic Antagonists; Protein Binding; Protein Structure, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M3 | 2020 |